Management of multiple sclerosis in COVID-19 pandemic

Anthony T Reder MD (

Dr. Reder of the University of Chicago received honorariums from Bayer, Biogen Idec, Caremark Rx, Genentech, Genzyme, Novartis, Mallinckrodt, Mylan, Serono, and Teva-Marion for service on advisory boards and as a consultant as well as stock options from NKMax America for advisory work.

)
Veronica P Cipriani MD MS (

Dr. Cipriani of the University of Chicago Medical Center received consulting fees from Genetech as an advisory board participant

)
Originally released: April 5, 2020; expires April 5, 2023

In response to the uncertainties concerning the management of multiple sclerosis during the pandemic, we asked Senior Associate Editor Dr. Anthony Reder to answer some key questions regarding COVID-19 and multiple sclerosis.

The content you are trying to view is available only to logged in, current MedLink Neurology subscribers.

If you are a subscriber, please log in.

If you are a former subscriber or have registered before, please log in first and then click select a Service Plan or contact Subscriber Services. Site license users, click the Site License Acces link on the Homepage at an authorized computer.

If you have never registered before, click Learn More about MedLink Neurology  or view available Service Plans.

Find out how you can join MedLink Neurology